<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Crit Care Med</journal-id><journal-id journal-id-type="pmc-domain-id">2372</journal-id><journal-id journal-id-type="pmc-domain">worldjccm</journal-id><journal-id journal-id-type="publisher-id">WJCCM</journal-id><journal-title-group><journal-title>World Journal of Critical Care Medicine</journal-title></journal-title-group><issn pub-type="epub">2220-3141</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11891851</article-id><article-id pub-id-type="pmcid-ver">PMC11891851.1</article-id><article-id pub-id-type="pmcaid">11891851</article-id><article-id pub-id-type="pmcaiid">11891851</article-id><article-id pub-id-type="pmid">40491879</article-id><article-id pub-id-type="doi">10.5492/wjccm.v14.i2.100844</article-id><article-id pub-id-type="other">jWJCCM.v14.i2.eid100844</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Retrospective Cohort Study</subject></subj-group></article-categories><title-group><article-title>Cannabis use disorder and severe sepsis outcomes in cancer patients: Insights from a national inpatient sample</article-title><alt-title>Sager AR <italic toggle="yes">et al</italic>. CUD and sepsis outcomes in cancer patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sager</surname><given-names initials="AR">Avinaash R</given-names></name><aff>Internal Medicine, St. Elizabeth&#8217;s Medical Center, Boston, MA 02135, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Desai</surname><given-names initials="R">Rupak</given-names></name><aff>Outcomes Research, Independent Researcher, Atlanta, GA 30033, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mylavarapu</surname><given-names initials="M">Maneeth</given-names></name><aff>Public Health, Adelphi University, Garden City, NY 11530, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shastri</surname><given-names initials="D">Dipsa</given-names></name><aff>Internal Medicine, East Tennessee State University, Johnson, TN 37614, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Devaprasad</surname><given-names initials="N">Nikitha</given-names></name><aff>Internal Medicine, SRM Medical College Hospital and Research Center, Potheri 603211, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thiagarajan</surname><given-names initials="SN">Shiva N</given-names></name><aff>Internal Medicine, SRM Medical College Hospital and Research Center, Potheri 603211, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chandramohan</surname><given-names initials="D">Deepak</given-names></name><aff>Department of Nephrology, University of Alabama at Birmingham, Birmingham, AL 35001, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Agrawal</surname><given-names initials="A">Anshuman</given-names></name><aff>Internal Medicine, Kasturba Hospital, Manipal 576104, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gada</surname><given-names initials="U">Urmi</given-names></name><aff>Infectious Diseases, Deenanath Hospital, Erandwane 411004, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jain</surname><given-names initials="A">Akhil</given-names></name><aff>Department of Hematology and Medical Oncology, University of Iowa Hospitals and Clinics, Iowa, IA 52242, United States. <email>akhiljaindr@gmail.com</email></aff></contrib></contrib-group><author-notes><fn><p>Co-first authors: Avinaash R Sager and Rupak Desai.</p><p>Author contributions: Sager AR, Desai R, and Jain A performed data curation, visualization, and interpretation; Sager AR and Desai R they contributed equally to this article, they are the co-first authors of this manuscript; Desai R has made significant contributions in terms of conceptualization, methodology, editorial work and executive analysis; Sager AR, Mylavarapu M, Shastri D, Devaprasad N, Thiagarajan SN, and Agrawal A wrote the manuscript; Desai R, Jain A, Mylavarapu M, Chandramohan D, and Gada U reviewed and edited the manuscript; and all authors have read and approved the final manuscript.</p><p>Corresponding author: Akhil Jain, MD, Department of Hematology and Medical Oncology, University of Iowa Hospitals and Clinics, 200 Hawkins, Iowa, IA 52242, United States. <email>akhiljaindr@gmail.com</email></p></fn></author-notes><pub-date pub-type="collection"><day>9</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2025</year></pub-date><volume>14</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">483815</issue-id><elocation-id>100844</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>8</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-10 09:25:15.120"><day>10</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/Licenses/by-nc/4.0/</uri></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="100844.pdf"/><abstract><sec><title>BACKGROUND</title><p>The burden of cannabis use disorder (CUD) in the context of its prevalence and subsequent cardiopulmonary outcomes among cancer patients with severe sepsis is unclear.</p></sec><sec><title>AIM</title><p>To address this knowledge gap, especially due to rising patterns of cannabis use and its emerging pharmacological role in cancer.</p></sec><sec><title>METHODS</title><p>By applying relevant International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes to the National Inpatient Sample database between 2016-2020, we identified CUD(+) and CUD(-) arms among adult cancer admissions with severe sepsis. Comparing the two cohorts, we examined baseline demographic characteristics, epidemiological trends, major adverse cardiac and cerebrovascular events, respiratory failure, hospital cost, and length of stay. We used the Pearson <italic toggle="yes">&#967;</italic><sup>2</sup> d test for categorical variables and the Mann-Whitney <italic toggle="yes">U</italic> test for continuous, non-normally distributed variables. Multivariable regression analysis was used to control for potential confounders. A <italic toggle="yes">P</italic> value &#8804; 0.05 was considered for statistical significance.</p></sec><sec><title>RESULTS</title><p>We identified a total of 743520 cancer patients admitted with severe sepsis, of which 4945 had CUD. Demographically, the CUD(+) cohort was more likely to be younger (median age = 58 <italic toggle="yes">vs</italic> 69, <italic toggle="yes">P</italic> &lt; 0.001), male (67.9% <italic toggle="yes">vs</italic> 57.2%, <italic toggle="yes">P</italic> &lt; 0.001), black (23.7% <italic toggle="yes">vs</italic> 14.4%, <italic toggle="yes">P</italic> &lt; 0.001), Medicaid enrollees (35.2% <italic toggle="yes">vs</italic> 10.7%, <italic toggle="yes">P</italic> &lt; 0.001), in whom higher rates of substance use and depression were observed. CUD(+) patients also exhibited a higher prevalence of chronic pulmonary disease but lower rates of cardiovascular comorbidities. There was no significant difference in major adverse cardiac and cerebrovascular events between CUD(+) and CUD(-) cohorts on multivariable regression analysis. However, the CUD(+) cohort had lower all-cause mortality (adjusted odds ratio = 0.83, 95% confidence interval: 0.7-0.97, <italic toggle="yes">P</italic> &lt; 0.001) and respiratory failure (adjusted odds ratio = 0.8, 95% confidence interval: 0.69-0.92, <italic toggle="yes">P</italic> = 0.002). Both groups had similar median length of stay, though CUD(+) patients were more likely to have higher hospital cost compared to CUD(-) patients (median = 94574 dollars <italic toggle="yes">vs</italic> 86615 dollars, <italic toggle="yes">P</italic> &lt; 0.001).</p></sec><sec><title>CONCLUSION</title><p>CUD(+) cancer patients with severe sepsis, who tended to be younger, black, males with higher rates of substance use and depression had paradoxically significantly lower odds of all-cause in-hospital mortality and respiratory failure. Future research should aim to better elucidate the underlying mechanisms for these observations.</p></sec></abstract><kwd-group><kwd>Cannabis/marijuana</kwd><kwd>Sepsis</kwd><kwd>Cardiovascular outcomes</kwd><kwd>Major adverse cardiac and cerebrovascular events</kwd><kwd>Pulmonological complications</kwd><kwd>Cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>Core Tip:</bold> Cannabis use disorder (CUD) in cancer patients with severe sepsis is associated with lower in-hospital mortality and respiratory failure despite higher rates of substance use and depression. CUD(+) patients, who are more likely to be younger, male, and black, also face increased hospital costs. These findings highlight the complex interplay between CUD and sepsis outcomes in cancer, suggesting the need for further research into the mechanisms behind these observations.</p><sec><title>INTRODUCTION</title><p>Cannabis use disorder (CUD) is defined by a set of diagnostic criteria, including patterns of gradually increasing intake, craving, unsuccessful attempts to limit use, disruptions in social and professional obligations, use in settings that pose physical harm, and the development of tolerance and withdrawal symptoms[<xref rid="B1" ref-type="bibr">1</xref>]. A meta-analysis of 21 studies identified that cannabis users have a one in five risk of developing CUD, and weekly or more frequent use increased the risk of cannabis dependence to one in three[<xref rid="B2" ref-type="bibr">2</xref>]. A study of Veterans Health Administration patients between 2005 and 2019 showed an increased prevalence of CUD over 14 years, from 1.38% to 2.25% in states where cannabis is not legal, 1.38% to 2.54% in states with medical cannabis laws only, and 1.40% to 2.56% in states with medical cannabis and recreational cannabis laws. However, the impact that legalization by state laws played on this up-trending pattern of use is relatively small and inconsistent across age groups, with the authors citing other possible factors like a concurrent rise in psychiatric and pain disorders, increased cannabis potency, decreasing public risk perception, and a lucrative cannabis industry as possibly playing a bigger role[<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Among cancer patients as well, age seems to play a role in cannabis use and perceptions about availability and risk. One study identified significantly higher use rates among those with past or recent cancer diagnosis in the middle age population compared to those without cancer, whereas this effect was not observed in younger or older age groups. Cousins <italic toggle="yes">et al</italic>[<xref rid="B4" ref-type="bibr">4</xref>] reported that 8.9% of total cancer patients and 9.9% of cancer patients who had been diagnosed in the past year had reported cannabis use. In general, increasing perceived risk and difficulty in access seemed to be a function of increasing age[<xref rid="B4" ref-type="bibr">4</xref>]. There are several approved cannabis-based medications on the market targeting a wide variety of cancer-related issues like chemotherapy-induced nausea and vomiting, fatigue, anorexia, and chronic pain[<xref rid="B5" ref-type="bibr">5</xref>]. A study among 2970 patients with advanced cancer between 2015 and 2017 showed 95.9% of patients reported improvement in palliative symptoms with cannabis use at six-month follow-up[<xref rid="B6" ref-type="bibr">6</xref>]. In 2019, the American Cancer Society estimated 1.7 million new cancer diagnoses and more than 600000 deaths[<xref rid="B7" ref-type="bibr">7</xref>]. Hence, advancing novel therapeutic modalities to address this morbidity and mortality burden is imperative.</p><p>In recent years, the anticancer effects of cannabis have been explored more. Some researchers have noted its potential for modulating tumor growth in several <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> models, though this effect seems to be dependent on the type of cancer and drug dosage[<xref rid="B8" ref-type="bibr">8</xref>]. For example, a 2021 meta-analysis of 34 studies revealed a negative association between non-testicular cancer and cannabis use, though this study was notable for a high degree of heterogeneity (<italic toggle="yes">I</italic><sup>2</sup> = 79.2%), obscuring the interpretation of its results[<xref rid="B9" ref-type="bibr">9</xref>]. Sepsis arises secondary to a dysregulation in the host response to infection, causing end-organ compromise that is life-threatening[<xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref>]. The incidence of sepsis or severe sepsis in cancer is variable in the literature. One large database study that included 29795 severe sepsis admissions with cancer found an overall incidence of 16.4 cases per 1000[<xref rid="B13" ref-type="bibr">13</xref>]. Another study found that across 19 million hospitalizations for sepsis between 2008 and 2017, one in five had concurrent cancer, with 80% of those being solid cancers[<xref rid="B14" ref-type="bibr">14</xref>]. Common sources are pulmonary, genitourinary, and abdominal, with gram-negative organisms like E. coli being most commonly encountered[<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>]. The rate of sepsis-related readmission appears higher in the cancer cohort <italic toggle="yes">vs</italic> the non-cancer cohort (6.2% <italic toggle="yes">vs</italic> 5.4%, <italic toggle="yes">P</italic> &lt; 0.001)[<xref rid="B17" ref-type="bibr">17</xref>]. A 2013-2014 study of the United States National Readmissions Database found higher rates of in-hospital mortality among cancer-related sepsis admissions <italic toggle="yes">vs</italic> non-cancer-related sepsis (27.9% <italic toggle="yes">vs</italic> 19.5%, <italic toggle="yes">P</italic> &lt; 0.001). Sepsis survivors also appear to have higher rates of all-cause mortality and major adverse cardiovascular events at long-term follow-up[<xref rid="B18" ref-type="bibr">18</xref>]. In contrast, a retrospective analysis of 20975 admissions between 2003 and 2014 demonstrated an improving trend in sepsis-associated mortality in cancer patients compared to those without cancer [adjusted (odds ratio) = 0.53, 95% confidence interval (CI): 0.45-0.63][<xref rid="B19" ref-type="bibr">19</xref>]. There is insufficient data on the impact of CUD on severe sepsis and subsequent cardiopulmonary outcomes in cancer patients, which we have studied and intend to provide a basis for further research on this topic.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Source</title><p>The National Inpatient Sample (NIS) is part of the Agency for Healthcare Research and Qualities Healthcare Cost and Utilization Project. We utilized the 2016-2020 dataset for our study. It is the largest public, all-payer dataset, and weighted survey analysis of the NIS datasets produces results that are representative estimates of the national outcomes[<xref rid="B20" ref-type="bibr">20</xref>]. As this database is de-identified to protect patient confidentiality, Institutional Review Board approval is not needed.</p></sec><sec><title>Study population</title><p>The study utilized the International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification diagnostic codes F12.1x and F12.2x (excluding F12.21 for dependence in remission) to identify cases of CUD, and R65.2x to identify cases of severe sepsis. The Revised Clinical Classifications Software was used to identify our two cohorts among all adult cancer patients admitted with severe sepsis between 2016 and 2020; specifically, the group with CUD(+) and the group without CUD(-)[<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>]. Both primary and secondary discharge diagnoses of severe sepsis and CUD were considered in distributing our cohorts (Figure <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>Flowchart of patient selection of study population.</bold> This flowchart depicts the selection process for hospitalized adult cancer patients with severe sepsis from the National Inpatient Sample database between 2016 and 2020. Total of the 10741427 hospitalized adult cancer patients, those without severe sepsis were excluded, resulting in a cohort of 743520 patients. This cohort was further divided into two groups: Those with cannabis use disorder (<italic toggle="yes">n</italic> = 4945) and those without cannabis use disorder (<italic toggle="yes">n</italic> = 738575). CUD: Cannabis use disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100844-g001.jpg"/></fig></sec><sec><title>Outcomes</title><p>Between the two cohorts, we compared patient demographics, hospital-specific features, and comorbidities among cancer patients admitted with severe sepsis. Primary outcomes were the prevalence and trends in CUD, major adverse cardiac and cerebrovascular events, and respiratory failure. Secondary outcomes were the hospital length of stay, cost, and impact on the utilization of healthcare resources.</p></sec><sec><title>Statistical analysis</title><p>IBM SPSS statistics (Version 25.0) with weighted data and complex sample modules with strata and cluster designs were used for our statistical analysis [IBM Corp. (2020). IBM SPSS statistics for Windows (Version 25.0) Armonk, NY: IBM Corp]. Categorical variables were expressed as percentages and continuous variables were expressed as medians with ranges between the 25<sup>th</sup> and 75<sup>th</sup> percentile. We used Pearson-chi squared test for categorical variables and Mann-Whitney <italic toggle="yes">U</italic> test for continuous non-normally distributed variables. Statistical significance was set at a <italic toggle="yes">P</italic> value of less than 0.05. Multivariable regression analysis was used to analyze primary outcomes after adjusting for age, sex, race, median household income, payer type, hospital bed size, hospital location and teaching status, hospital region and patient comorbidities. Results of this regression analysis were expressed as adjusted OR with 95%CI and <italic toggle="yes">P</italic> values.</p></sec></sec><sec><title>RESULTS</title><sec><title>Epidemiology and patient characteristics</title><p>We identified a total of 743520 adult (&#8805; 18 years) cancer patients who were hospitalized with a primary discharge diagnosis of severe sepsis between 2016-2020. Out of these total hospitalizations, 4945 patients had a secondary diagnosis of CUD while 738575 patients served as control. The prevalence of severe sepsis with CUD was found to be 4.6%. Figure <xref rid="F2" ref-type="fig">2A</xref> depicts the trends in cannabis use among hospitalized cancer patients with severe sepsis. We compared the baseline demographics, hospital-specific characteristics, and comorbidities between the two cohorts (Table <xref rid="T1" ref-type="table">1</xref>). Severe sepsis hospitalizations with CUD(+) cohort consisted of predominantly younger population (median age 58 years <italic toggle="yes">vs</italic> 69 years), males (67.9% <italic toggle="yes">vs</italic> 32.1%), blacks (23.7 <italic toggle="yes">vs</italic> 14.4%), low median income population (0-25<sup>th</sup> quartile 36.7% <italic toggle="yes">vs</italic> 27.2%), and Medicaid enrollees (35.2% <italic toggle="yes">vs</italic> 10.7%). Among hospitals in the west, there were more hospitalizations for severe sepsis among cancer patients with CUD than without (34.1% <italic toggle="yes">vs</italic> 24.2%) (Table <xref rid="T1" ref-type="table">1</xref>, Figure <xref rid="F2" ref-type="fig">2B</xref>). We included patients with both hematological malignancies (leukemia and lymphoma) as well as non-hematological malignancies in our study. There was no statistically significant difference in the distribution of these malignancies in both cohorts (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://f6publishing.blob.core.windows.net/a3d1ef45-b306-44b3-8f33-e1447a4f7bd6/100844-supplementary-material.pdf">Supplementary Table 1</uri>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Epidemiology and patient characteristics.</bold> A: Trends in cannabis use among hospitalized cancer patients with severe sepsis. This line graph displays the proportion of patients receiving vasopressors during their hospitalization over a five-year period. Trends are shown for the total patient population, as well as for males and females separately; B: Comparison of comorbidities between cannabis use disorder (CUD) (+) and CUD(-) cohorts, expressed as percentages. This figure displays the percentage of patients with various comorbidities in the two cohorts: Those with and without CUD. HLD: Hypomyelinating leukodystrophy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100844-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographics, hospital-specific admitting characteristics and co-morbidities among cancer patients admitted for severe sepsis with <italic toggle="yes">vs</italic> without cannabis use disorder</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Baseline characteristics of cancer patients hospitalized with severe sepsis (<italic toggle="yes">n</italic> = 743520)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>CUD(-) (<italic toggle="yes">n</italic> = 738575)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>CUD(+) (<italic toggle="yes">n</italic> = 4945)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
<hr/>
</td></tr></thead><tbody><tr><td colspan="4" rowspan="1">Demographics</td></tr><tr><td rowspan="1" colspan="1">Age at admission, years (median with 25<sup>th</sup>-75<sup>th</sup> percentile values)</td><td rowspan="1" colspan="1">69 (61-77)</td><td rowspan="1" colspan="1">58 (49-64)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Males</td><td rowspan="1" colspan="1">57.2</td><td rowspan="1" colspan="1">67.9</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Females</td><td rowspan="1" colspan="1">42.8</td><td rowspan="1" colspan="1">32.1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">70.8</td><td rowspan="1" colspan="1">64.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Black</td><td rowspan="1" colspan="1">14.4</td><td rowspan="1" colspan="1">23.7</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Hispanic</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Asian or Pacific Islander</td><td rowspan="1" colspan="1">4.3</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Native American</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Median household income<xref rid="T1FN1" ref-type="table-fn">1</xref></td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">0<sup>th</sup>-25<sup>th</sup></td><td rowspan="1" colspan="1">27.2</td><td rowspan="1" colspan="1">36.7</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">26<sup>th</sup>-50<sup>th</sup></td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">26.9</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">51<sup>th</sup>-75<sup>th</sup></td><td rowspan="1" colspan="1">24.6</td><td rowspan="1" colspan="1">21.5</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">76<sup>th</sup>-100<sup>th</sup></td><td rowspan="1" colspan="1">23.2</td><td rowspan="1" colspan="1">14.9</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Payer type</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Medicare</td><td rowspan="1" colspan="1">66.1</td><td rowspan="1" colspan="1">38.2</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Medicaid</td><td rowspan="1" colspan="1">10.7</td><td rowspan="1" colspan="1">35.2</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Private</td><td rowspan="1" colspan="1">21.4</td><td rowspan="1" colspan="1">22.4</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Self-pay</td><td rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">4.1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">No charge</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Hospital-specific admitting characteristics</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Hospital location and teaching status<xref rid="T1FN2" ref-type="table-fn">2</xref></td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Rural</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">5.6</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Urban non-teaching</td><td rowspan="1" colspan="1">19.5</td><td rowspan="1" colspan="1">15.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Urban teaching</td><td rowspan="1" colspan="1">74.5</td><td rowspan="1" colspan="1">78.7</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Hospital region</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Northeast</td><td rowspan="1" colspan="1">17.9</td><td rowspan="1" colspan="1">10.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Midwest</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">20.3</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">South</td><td rowspan="1" colspan="1">36.8</td><td rowspan="1" colspan="1">34.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">West</td><td rowspan="1" colspan="1">24.2</td><td rowspan="1" colspan="1">34.1</td><td rowspan="1" colspan="1">-</td></tr><tr><td colspan="4" rowspan="1">Comorbidities</td></tr><tr><td rowspan="1" colspan="1">Acquired immunodeficiency syndrome</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Diabetes without chronic complications</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">7.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Diabetes with chronic complications</td><td rowspan="1" colspan="1">18.8</td><td rowspan="1" colspan="1">12.9</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Hypertension, complicated</td><td rowspan="1" colspan="1">29.6</td><td rowspan="1" colspan="1">19.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Hypertension, uncomplicated</td><td rowspan="1" colspan="1">29.4</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">Hyperlipidemia</td><td rowspan="1" colspan="1">31.1</td><td rowspan="1" colspan="1">20.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Chronic pulmonary disease</td><td rowspan="1" colspan="1">26.1</td><td rowspan="1" colspan="1">34.8</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Obesity</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">10.4</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Peripheral vascular disease</td><td rowspan="1" colspan="1">7.6</td><td rowspan="1" colspan="1">8.2</td><td rowspan="1" colspan="1">0.11</td></tr><tr><td rowspan="1" colspan="1">Hypothyroidism</td><td rowspan="1" colspan="1">13.2</td><td rowspan="1" colspan="1">7.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Valvular disease</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Tobacco use</td><td rowspan="1" colspan="1">25.2</td><td rowspan="1" colspan="1">28.8</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Alcohol abuse</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">13.1</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Cocaine use</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">6.9</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Depression</td><td rowspan="1" colspan="1">9.8</td><td rowspan="1" colspan="1">16.2</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Prior myocardial infarction</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">0.521</td></tr><tr><td rowspan="1" colspan="1">Prior transient ischemic attack or stroke</td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">Prior cancer</td><td rowspan="1" colspan="1">15.3</td><td rowspan="1" colspan="1">14.3</td><td rowspan="1" colspan="1">0.038</td></tr><tr><td rowspan="1" colspan="1">Prior chemotherapy</td><td rowspan="1" colspan="1">9.6</td><td rowspan="1" colspan="1">12.2</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Prior radiotherapy</td><td rowspan="1" colspan="1">6.6</td><td rowspan="1" colspan="1">8.9</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Autoimmune conditions</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2.2</td><td rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><label>1</label><p>Quartile classification of estimated median household income based on patients' ZIP code, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nrdnote.jsp">https://hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nrdnote.jsp</uri></p></fn><fn id="T1FN2"><label>2</label><p>A teaching hospital is one that has at least one Accreditation Council for Graduate Medical Education-approved residency program. Urban/rural classification is designated by Core Based Statistical Area, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/db/vars/hosp_bedsize/nrdnote.jsp">https://hcup-us.ahrq.gov/db/vars/hosp_bedsize/nrdnote.jsp</uri></p></fn><fn><p>Values are in percentages unless specified. Accompanying <italic toggle="yes">P</italic> value for significance. CUD: Cannabis use disorder.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Associated comorbidities</title><p>Comorbidities including chronic pulmonary disease (34.8% <italic toggle="yes">vs</italic> 26.1%), depression (16.2 <italic toggle="yes">vs</italic> 9.8%), alcohol abuse (13.1% <italic toggle="yes">vs</italic> 2.9%), and tobacco use (28.8% <italic toggle="yes">vs</italic> 25.2%) were significantly more in the CUD(+) cohort than CUD(-) cohort. Diabetes mellitus with complications (18.8% <italic toggle="yes">vs</italic> 12.9%), hyperlipidemia (31.1% <italic toggle="yes">vs</italic> 20.3%), and obesity (12% <italic toggle="yes">vs</italic> 10.4%) were significantly higher in the CUD(-) cohort. Other comorbidities were not significantly different in both cohorts (Table <xref rid="T1" ref-type="table">1</xref> and Figure <xref rid="F2" ref-type="fig">2B</xref>).</p></sec><sec><title>Cardiopulmonary outcomes</title><p>There was no significant difference in major adverse cardiac and cerebrovascular events in both cohorts (adjusted OR = 0.86, 95%CI: 0.74-1.01, <italic toggle="yes">P</italic> = 0.059). There was no significant difference in the odds of acute myocardial infarction, cardiac arrest, and acute ischemic stroke. However, the odds of respiratory failure were lower in the CUD(+) cohort (adjusted OR = 0.8, 95%CI: 0.69-0.92, <italic toggle="yes">P</italic> = 0.002) (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Primary and secondary in-hospital outcomes among cancer patients admitted for severe sepsis with <italic toggle="yes">vs</italic> without cannabis use disorder</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Outcomes</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>CUD(-) (<italic toggle="yes">n</italic> = 738575)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>CUD(+) (<italic toggle="yes">n</italic> = 4945)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">MACCE</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">28.4</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">All-cause in-hospital mortality</td><td rowspan="1" colspan="1">30.5</td><td rowspan="1" colspan="1">23.4</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Acute myocardial infarction</td><td rowspan="1" colspan="1">7.2</td><td rowspan="1" colspan="1">5.5</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Cardiac arrest, ventricular fibrillationand ventricular flutter</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.038</td></tr><tr><td rowspan="1" colspan="1">Acute ischemic stroke</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">0.207</td></tr><tr><td rowspan="1" colspan="1">Respiratory failure</td><td rowspan="1" colspan="1">50.9</td><td rowspan="1" colspan="1">48.6</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Disposition of patient<xref rid="T2FN1" ref-type="table-fn">1</xref></td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Routine</td><td rowspan="1" colspan="1">18.8</td><td rowspan="1" colspan="1">31.5</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Transfer to short term facility</td><td rowspan="1" colspan="1">3.4</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Other transfers (SNF, ICF <italic toggle="yes">etc.</italic>)</td><td rowspan="1" colspan="1">25.8</td><td rowspan="1" colspan="1">17.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Home healthcare</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">21.8</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Length of stay (median, days)</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0.034</td></tr><tr><td rowspan="1" colspan="1">Total cost of hospitalization (median, USD)</td><td rowspan="1" colspan="1">86615</td><td rowspan="1" colspan="1">94574</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><label>1</label><p>Disposition is at time of discharge and subject to state-specific differences in classification, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/db/vars/disp/nisnote.jsp">https://hcup-us.ahrq.gov/db/vars/disp/nisnote.jsp</uri></p></fn><fn><p>Values are in percentages unless stated. Accompanying 95% confidence intervals and <italic toggle="yes">P</italic> values for significance. CUD: Cannabis use disorder; MACCE: Major adverse cardiac and cerebrovascular events; SNF: Skilled nursing facility, ICF: Intermediate care facility; USD: United States dollar.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Inpatient mortality</title><p>All-cause mortality during hospitalization was found to be less in severe sepsis patients in the CUD(+) cohort compared to the CUD(-) cohort (2.9% <italic toggle="yes">vs</italic> 4.7%, <italic toggle="yes">P</italic> &lt; 0.001). A multivariate regression analysis was performed to assess the inpatient all-cause mortality, which showed lower odds of mortality (adjusted OR = 0.83, 95%CI: 0.7-0.9, <italic toggle="yes">P</italic> = 0.002) in severe sepsis patients with CUD compared to the CUD(-) cohort (Tables <xref rid="T2" ref-type="table">2</xref> and <xref rid="T3" ref-type="table">3</xref>, Figure <xref rid="F3" ref-type="fig">3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>
<bold>Forest plot demonstrating primary outcomes.</bold> This forest plot displays the adjusted odds ratios and 95% confidence intervals for various in-hospital outcomes among patients with cannabis use disorder compared to those without cannabis use disorder. RF: Respiratory failure; AIS: Acute ischemic stroke; CA: Cardiac arrest; VF: Ventricular fibrillation; Vf: Ventricular flutter; AMI: Acute myocardial infarction; MACCE: Major adverse cardiac and cerebrovascular event.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100844-g003.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Multivariable regression analysis of primary outcomes comparing cancer patients admitted for severe sepsis with <italic toggle="yes">vs</italic> without cannabis use disorder</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Events</bold>
</td><td rowspan="1" colspan="1">
<bold>Adjusted OR</bold>
</td><td rowspan="1" colspan="1">
<bold>95%CI</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">MACCE</td><td rowspan="1" colspan="1">0.86</td><td rowspan="1" colspan="1">0.74-1.01</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">All-cause in-hospital mortality</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">0.7-0.97</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">Acute myocardial infarction</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.77-1.37</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">Cardiac arrest, ventricular fibrillationand ventricular flutter</td><td rowspan="1" colspan="1">1.14</td><td rowspan="1" colspan="1">0.51-2.52</td><td rowspan="1" colspan="1">0.754</td></tr><tr><td rowspan="1" colspan="1">Acute ischemic stroke</td><td rowspan="1" colspan="1">0.89</td><td rowspan="1" colspan="1">0.53-1.5</td><td rowspan="1" colspan="1">0.671</td></tr><tr><td rowspan="1" colspan="1">Respiratory failure</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.69-0.92</td><td rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn><p>Values are as adjusted odds ratios. Accompanying 95% confidence intervals and <italic toggle="yes">P</italic> values for significance. Factors adjusted for are age, sex, race, median household income, payer type, elective status, hospital bed size, hospital location and teaching status, hospital region, acquired immunodeficiency syndrome, autoimmune conditions, depression, diabetes with and without chronic complications, hypertension (complicated and uncomplicated), hyperlipidemia, chronic pulmonary disease, obesity, peripheral vascular disease, hypothyroidism, valvular disease, drug abuse, alcohol abuse, smoker status, cocaine abuse, prior myocardial infarction, prior transient ischemic attack or stroke, and prior cancer history. OR; Odds ratio; CI: Confidence interval; MACCE: Major adverse cardiac and cerebrovascular events.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Trends in cannabis use among hospitalized cancer patients with severe sepsis - 2016-2020</title><p>There was a significant linear upward trend in the incidence of acute MI in severe sepsis patients with CUD compared to the non-CUD cohort from 2016-2020 (<italic toggle="yes">P</italic> trend &lt; 0.001). However, there was no significant linear trend in death during hospitalizations and respiratory failure in the CUD cohort from 2016 to 2020 (Figure <xref rid="F4" ref-type="fig">4</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p>
<bold>Trends in primary outcomes among cancer patients with cannabis use disorder admitted with severe sepsis.</bold> This line graph illustrates the percentage of patients experiencing specific in-hospital outcomes over five years. MACCE: Major adverse cardiac and cerebrovascular event.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100844-g004.jpg"/></fig></sec><sec><title>Secondary outcomes</title><p>Though the median length of hospitalization stay was similar in both cohorts (7 days), there was a statistical difference in the length of stay with a <italic toggle="yes">P</italic> value of 0.034, suggesting a difference in the distribution of the length of stay between the two cohorts. The cost of hospitalization was found to be significantly higher in the CUD cohort compared to the non-CUD cohort (median cost 94574 dollars <italic toggle="yes">vs</italic> 86615 dollars, <italic toggle="yes">P</italic> &lt; 0.001) (Tables <xref rid="T2" ref-type="table">2</xref> and <xref rid="T3" ref-type="table">3</xref>).</p></sec></sec><sec><title>DISCUSSION</title><p>In our study of cancer patients admitted with severe sepsis, the CUD(+) cohort was more likely to be younger, male, black, and Medicaid enrollees. They had lower rates of cardiovascular comorbidities but higher rates of chronic pulmonary disease, substance use, and depression. They had lower odds of all-cause mortality and respiratory failure, but higher median cost of hospital stay compared to the CUD(-) cohort. In line with our findings, several authors have also previously examined the higher rates of cannabis use and dependence among young adults and blacks[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B23" ref-type="bibr">23</xref>-<xref rid="B25" ref-type="bibr">25</xref>]. Furthermore, we report higher rates of CUD in hospitals based in the western United States. This is reflective of data from the Substance Abuse and Mental Health Services Administration&#8217;s 2021 National Survey on Drug Use and Health, where the Western states of Washington, Oregon, Nevada, and California reported the highest rates of marijuana use[<xref rid="B26" ref-type="bibr">26</xref>].</p><p>Our study revealed higher rates of comorbid alcohol use (13.1% <italic toggle="yes">vs</italic> 2.9%) and mood disorders (16.2% <italic toggle="yes">vs</italic> 9.8%) amongst the CUD(+) arm. Though concurrent alcohol and CUD are understudied, some authors have noted a significant two-way association between major depressive disorder and concurrent alcohol and cannabis use[<xref rid="B27" ref-type="bibr">27</xref>]. One primary care-based electronic health record study reported significantly higher odds for other substance use and most mental health conditions, including social anxiety, bipolar disorder, and depression, among those with CUD or cannabis use[<xref rid="B28" ref-type="bibr">28</xref>]. We, too, find that patients with CUD were more likely to have higher rates of concomitant depression. Animal studies have explored the neuromodulatory effects of cannabis on gamma-aminobutyric acid and glutamate neurotransmission, though this is still of unclear clinical significance[<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>].</p><p>A nationally representative 2018 survey of medical oncologists reported that nearly half (46%) recommend medical marijuana to their patients[<xref rid="B31" ref-type="bibr">31</xref>]. From a patient perspective, active users most often cited cannabis use for physical and neuropsychiatric symptoms, including pain, poor sleep or appetite, nausea, low mood and stress[<xref rid="B32" ref-type="bibr">32</xref>]. Interestingly, one study of cancer patients undergoing treatment noted that those using cannabis also tended to report more severe symptoms, though whether this is linked to cannabis use is unclear due to the cross-sectional design[<xref rid="B25" ref-type="bibr">25</xref>]. A multivariable analysis of different cancers found a statistically significant association between patients with gastrointestinal cancers and cannabis use[<xref rid="B33" ref-type="bibr">33</xref>]. A minority of patients discuss cannabis use with their healthcare providers or have medical authorization for its usage, with rates of around 25% and 30% respectively[<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>].</p><p>A cross-sectional study of 905 participants in Australia found comparable rates of CUD (32%) among those who used cannabis medically <italic toggle="yes">vs</italic> those who reported illicit use, with withdrawal and tolerance symptoms being the most common manifestations[<xref rid="B35" ref-type="bibr">35</xref>]. Another study found that around 80% of medical users also report recreational use and are more prone to daily usage, highlighting the overlap between medical and recreational cannabis use[<xref rid="B36" ref-type="bibr">36</xref>]. The significance of these study findings are underscored by data that suggest important gaps in medical literacy among regular cannabis users on its health effects, with a tendency to underestimate risks and overestimate benefits[<xref rid="B37" ref-type="bibr">37</xref>]. In fact, evidence-based studies regarding the potential risks and benefits of medical cannabis have been heterogeneous and inconsistent[<xref rid="B38" ref-type="bibr">38</xref>-<xref rid="B40" ref-type="bibr">40</xref>]. In part, this is due to its federal status as a Class I narcotic, limiting research funding[<xref rid="B41" ref-type="bibr">41</xref>].</p><p>Cannabinoids (CBs), the most well-researched chemical compound of cannabis, exert their action in the human body <italic toggle="yes">via</italic> the endocannabinoid system and are classified pharmacologically into the intoxicating tetrahydrocannabinol, non-intoxicating cannabidiol (CBD) and several other minor, less well-studied CBs[<xref rid="B42" ref-type="bibr">42</xref>]. Experiments investigating the cardiovascular effects of CBD in various pathological states have exhibited a wide range of effects. For example, reductions in stress related hypertension, not causing hypotension in animal hypertension models as well as vascular and cardiac protection in models of diabetes, sepsis and MI[<xref rid="B43" ref-type="bibr">43</xref>]. There is also a fair amount of basic science data supporting the ability of CBs to attenuate inflammatory pathways and oxidative stress by downregulating pro-inflammatory cytokines in sepsis[<xref rid="B44" ref-type="bibr">44</xref>-<xref rid="B47" ref-type="bibr">47</xref>]. Though much of this research has focused on CBD and tetrahydrocannabinol, more recent studies have also demonstrated similar anti-inflammatory properties during the lipopolysaccharide-induced, macrophage-mediated, cytokine storm of sepsis among minor cannabinoid groups like tetrahydrocannabivarin, cannabichromene, and cannabinol[<xref rid="B48" ref-type="bibr">48</xref>]. Some authors have also cited its anticancer potential through a diverse range of mechanisms like inducing apoptosis, inhibiting cancer signaling, cell proliferation, and angiogenesis <italic toggle="yes">via</italic> CB receptors expressed on tumor cells[<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>]. In contrast, a mendelian randomization study reported an increased risk for squamous cell lung carcinoma in individuals with genetic predisposition towards cannabis use[<xref rid="B51" ref-type="bibr">51</xref>]. An important consideration here also is the pharmacological interaction between CBs and conventional cancer therapies. Some studies have noted its ability to act synergistically alongside certain chemotherapy agents like paclitaxel, for example, through its effect on transport channels, increasing intracellular drug concentrations[<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>]. A 2021, phase 1b randomized, placebo controlled trial of 21 patients with recurrent glioblastoma being treated with temozolomide demonstrated improved one year survival rates in the intervention arm, which was concurrently administered the cannabis formulation, nabiximols (83% <italic toggle="yes">vs</italic> 44%, <italic toggle="yes">P</italic> = 0.042), though this study was not adequately powered to compare outcomes[<xref rid="B54" ref-type="bibr">54</xref>]. However, others have highlighted the contradictory effect of CBs in reducing the efficacy of certain agents, like immunotherapy and metal based drugs, through the modulation of T cell function and production of detoxifying proteins, respectively[<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>].</p><p>The link between inflammation, sepsis, and its subsequent adverse consequences like shock, metabolic acidosis and end-organ dysfunction is through the systemic inflammatory response syndrome, during which there is a hypermetabolic accumulation of hydrogen peroxide[<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B57" ref-type="bibr">57</xref>]. Hence, reducing maladaptive inflammation could be an important component of future therapeutic options aiming to improve outcomes in sepsis[<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B59" ref-type="bibr">59</xref>]. For example, a mouse sepsis experiment demonstrated decreased systemic inflammation, as well as cardiac and renal protective effects in mice injected with CBD compared to controls[<xref rid="B60" ref-type="bibr">60</xref>]. There have been other observational data with concurrent findings of paradoxically improved outcomes among cannabis users. One NIS study between 2005 and 2014 found that among 6073862 COPD admissions, those with cannabis use (0.4%) had statistically significantly lower odds of in-hospital mortality and pneumonia compared to those without cannabis use (99.6%). The cannabis use cohort also had lower odds of sepsis and respiratory failure, but this did not reach statistical significance[<xref rid="B61" ref-type="bibr">61</xref>]. In another cross-sectional analysis of the NIS database between 2007-2011, multivariable logistic regression showed lower in-hospital mortality among cancer patients with active marijuana use <italic toggle="yes">vs</italic> non-users (OR = 0.44, 95%CI: 0.35-0.55)[<xref rid="B62" ref-type="bibr">62</xref>]. In a retrospective cohort study of 510007 vascular surgery patients, those with CUD had a lower incidence of sepsis in the perioperative period (OR = 0.64, 95%CI: 0.47-0.85), though this association was not statistically significant on sensitivity analysis[<xref rid="B63" ref-type="bibr">63</xref>]. In contrast, there have also been studies showing cannabis use to be associated with higher risk for some adverse outcomes. For example, a mendelian randomization study of patients with genetic liability for cannabis use identified a greater risk for small vessel strokes and atrial fibrillation on multivariate analysis[<xref rid="B64" ref-type="bibr">64</xref>]. Another population-level cohort study comparing individuals reporting cannabis use within one year to propensity-matched controls found that the cannabis use group had significantly higher rates of emergency room visits and hospital admissions, though there was no difference in all-cause mortality (OR = 0.99, 95%CI: 0.49-2.02)[<xref rid="B65" ref-type="bibr">65</xref>].</p><p>The major strength of our study is that it utilizes the largest inpatient dataset, which encompasses hospitalizations across 47 states participating in Healthcare Cost and Utilization Project, approximating around 97% of the United States population, or around 7 million unweighted and 35 million weighted admissions nationwide. This allows for an analysis of trends and outcomes across various sociodemographic factors and co-morbidities. As a result, clinicians can better understand nationwide patterns, associations and disease burden. However, our study also has some limitations. The major limitation is that, as a population level administrative dataset, the NIS collects data from admission related International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes and not individual patients. Additionally, through the retrospective cohort design, there is a possibility of unmeasured confounding factors, selection, and sampling bias. Hence, no causality can be inferred regarding outcomes of CUD in sepsis among cancer patients. Furthermore, data regarding prior <italic toggle="yes">vs</italic> current cancer, chemotherapy regimen, age related variations in cancer profile, laboratory and microbiological data and the source of sepsis could not be assessed, which may have influenced the findings in our study by introducing uncontrolled confounders. Despite these limitations, we provide contemporary results from the largest database for outcomes of severe sepsis in cancer patients with CUD.</p><p>Prospective cohort studies with standardized data collection on cancer staging, treatment history, and microbiological data can help better account for these variables and improve the robustness of the study findings. Additionally, further research is needed to continue to elucidate the underlying immunological mechanisms of how cannabis use may influence the prognosis of critically ill patients. Furthermore, our study emphasizes the need for heightened awareness of CUD among cancer patients and its potential effects on sepsis outcomes. Healthcare providers need education on this relationship to deliver informed care. Importantly, policies should promote access to treatment for CUD treatment and support integrated care models for this vulnerable population.</p></sec><sec><title>CONCLUSION</title><p>Our study is unique in investigating the implications of CUD on severe sepsis outcomes in the cancer population. We found among cancer patients with severe sepsis, those with CUD tended to be younger, black, male, Medicaid enrollees and had higher rates of substance use disorder, depression, chronic pulmonary disease and healthcare utilization cost. However, they had lower rates of cardiovascular co-morbidities and paradoxically lower odds of all-cause mortality and respiratory failure on multivariable regression analysis. A possible link in unraveling this paradox is the potential for CBs to modulate the systemic inflammatory response syndrome of sepsis.</p><p>With the increasing prevalence of cannabis use, we aim to inform clinicians about the importance of understanding how CUD affects sepsis in cancer patients. Focusing on the presence of CUD among these patients can enhance care and management. Furthermore, future studies with prospective designs would allow for better control of confounders and more robust conclusions. Additionally, research should also aim to clarify the underlying pathophysiological mechanisms of CUD in sepsis and investigate potential therapeutic options. In the interim, we express concern over findings in the present literature which suggest significantly overlapping recreational and medicinal usage of cannabis and low disclosure rates of such use in the physician-patient relationship, consequently limiting informed decision making and predisposing cancer patients towards CUD without clear medical benefit.</p></sec></body><back><fn-group><fn><p>
<bold>Institutional review board statement:</bold> We used a publicly available anonymous national database with de-identified patient information and therefore did not require Institutional Review Board approval.</p></fn><fn><p>
<bold>Informed consent statement:</bold> We used a publicly available anonymous national database without any way to trace the identity of the patients, and therefore, informed consent was not obtained.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict-of-interest statement:</bold> All the authors report no relevant conflicts of interest for this article.</p></fn><fn><p>
<bold>STROBE statement:</bold> The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.</p></fn><fn><p>
<bold>Provenance and peer review:</bold> Invited article; Externally peer reviewed.</p></fn><fn><p>
<bold>Peer-review model:</bold> Single blind</p></fn><fn><p>
<bold>Specialty type:</bold> Critical care medicine</p></fn><fn><p>
<bold>Country of origin:</bold> United States</p></fn><fn><p>
<bold>Peer-review report&#8217;s classification</bold>
</p></fn><fn><p>
<bold>Scientific Quality:</bold> Grade A, Grade B, Grade C</p></fn><fn><p>
<bold>Novelty:</bold> Grade A, Grade B, Grade C</p></fn><fn><p>
<bold>Creativity or Innovation:</bold> Grade A, Grade B, Grade C</p></fn><fn><p>
<bold>Scientific Significance:</bold> Grade A, Grade B, Grade B</p></fn><fn><p>
<bold>P-Reviewer:</bold> Yanik F; Zhu LM <bold>S-Editor:</bold> Bai Y <bold>L-Editor:</bold> A <bold>P-Editor:</bold> Zhang YL</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>YC</given-names></name></person-group><comment>The DSM: 5 Criteria of cannabis use disorder: Methods and applications. In: Martin CR, Patel VB, Preedy VR, editor. Cannabis Use, Neurobiology, Psychology, and Treatment. Amsterdam: Elsevier, 2023: 499-510</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>GCK</given-names></name><name name-style="western"><surname>Hides</surname><given-names>L</given-names></name><name name-style="western"><surname>Hall</surname><given-names>WD</given-names></name></person-group><article-title>What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis</article-title><source>Addict Behav</source><year>2020</year><volume>109</volume><fpage>106479</fpage><pub-id pub-id-type="pmid">32485547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2020.106479</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasin</surname><given-names>DS</given-names></name><name name-style="western"><surname>Wall</surname><given-names>MM</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Alschuler</surname><given-names>DM</given-names></name><name name-style="western"><surname>Malte</surname><given-names>C</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gradus</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></name><name name-style="western"><surname>Maynard</surname><given-names>CC</given-names></name><name name-style="western"><surname>Keyhani</surname><given-names>S</given-names></name><name name-style="western"><surname>Martins</surname><given-names>SS</given-names></name><name name-style="western"><surname>Fink</surname><given-names>DS</given-names></name><name name-style="western"><surname>Livne</surname><given-names>O</given-names></name><name name-style="western"><surname>Mannes</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>S</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>AJ</given-names></name></person-group><article-title>State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019</article-title><source>JAMA Psychiatry</source><year>2023</year><volume>80</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">36857036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2023.0019</pub-id><pub-id pub-id-type="pmcid">PMC9979011</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cousins</surname><given-names>MM</given-names></name><name name-style="western"><surname>Jannausch</surname><given-names>ML</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>LN</given-names></name><name name-style="western"><surname>Jagsi</surname><given-names>R</given-names></name><name name-style="western"><surname>Ilgen</surname><given-names>MA</given-names></name></person-group><article-title>Prevalence of cannabis use among individuals with a history of cancer in the United States</article-title><source>Cancer</source><year>2021</year><volume>127</volume><fpage>3437</fpage><lpage>3444</lpage><pub-id pub-id-type="pmid">34081772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33646</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legare</surname><given-names>CA</given-names></name><name name-style="western"><surname>Raup-Konsavage</surname><given-names>WM</given-names></name><name name-style="western"><surname>Vrana</surname><given-names>KE</given-names></name></person-group><article-title>Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals</article-title><source>Pharmacology</source><year>2022</year><volume>107</volume><fpage>131</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">35093949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000521683</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-Lev</surname><given-names>Schleider L</given-names></name><name name-style="western"><surname>Mechoulam</surname><given-names>R</given-names></name><name name-style="western"><surname>Lederman</surname><given-names>V</given-names></name><name name-style="western"><surname>Hilou</surname><given-names>M</given-names></name><name name-style="western"><surname>Lencovsky</surname><given-names>O</given-names></name><name name-style="western"><surname>Betzalel</surname><given-names>O</given-names></name><name name-style="western"><surname>Shbiro</surname><given-names>L</given-names></name><name name-style="western"><surname>Novack</surname><given-names>V</given-names></name></person-group><article-title>Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer</article-title><source>Eur J Intern Med</source><year>2018</year><volume>49</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">29482741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejim.2018.01.023</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2019</article-title><source>CA Cancer J Clin</source><year>2019</year><volume>69</volume><fpage>7</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">30620402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21551</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dari&#353;</surname><given-names>B</given-names></name><name name-style="western"><surname>Tancer</surname><given-names>Verboten M</given-names></name><name name-style="western"><surname>Knez</surname><given-names>&#381;</given-names></name><name name-style="western"><surname>Ferk</surname><given-names>P</given-names></name></person-group><article-title>Cannabinoids in cancer treatment: Therapeutic potential and legislation</article-title><source>Bosn J Basic Med Sci</source><year>2019</year><volume>19</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">30172249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bjbms.2018.3532</pub-id><pub-id pub-id-type="pmcid">PMC6387667</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>TM</given-names></name></person-group><article-title>Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States</article-title><source>Cannabis Cannabinoid Res</source><year>2021</year><volume>6</volume><fpage>413</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">33998861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/can.2019.0095</pub-id><pub-id pub-id-type="pmcid">PMC8612444</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>CS</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name><name name-style="western"><surname>Annane</surname><given-names>D</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>GR</given-names></name><name name-style="western"><surname>Chiche</surname><given-names>JD</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Levy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name><name name-style="western"><surname>Martin</surname><given-names>GS</given-names></name><name name-style="western"><surname>Opal</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rubenfeld</surname><given-names>GD</given-names></name><name name-style="western"><surname>van</surname><given-names>der Poll T</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name></person-group><article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>L</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name></person-group><article-title>Sepsis and septic shock</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">29937192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30696-2</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>L</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>CM</given-names></name><name name-style="western"><surname>French</surname><given-names>C</given-names></name><name name-style="western"><surname>Machado</surname><given-names>FR</given-names></name><name name-style="western"><surname>Mcintyre</surname><given-names>L</given-names></name><name name-style="western"><surname>Ostermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name><name name-style="western"><surname>Schorr</surname><given-names>C</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>S</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Alshamsi</surname><given-names>F</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><name name-style="western"><surname>Arabi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>L</given-names></name><name name-style="western"><surname>Beale</surname><given-names>R</given-names></name><name name-style="western"><surname>Beilman</surname><given-names>G</given-names></name><name name-style="western"><surname>Belley-Cote</surname><given-names>E</given-names></name><name name-style="western"><surname>Burry</surname><given-names>L</given-names></name><name name-style="western"><surname>Cecconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Centofanti</surname><given-names>J</given-names></name><name name-style="western"><surname>Coz</surname><given-names>Yataco A</given-names></name><name name-style="western"><surname>De</surname><given-names>Waele J</given-names></name><name name-style="western"><surname>Dellinger</surname><given-names>RP</given-names></name><name name-style="western"><surname>Doi</surname><given-names>K</given-names></name><name name-style="western"><surname>Du</surname><given-names>B</given-names></name><name name-style="western"><surname>Estenssoro</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>R</given-names></name><name name-style="western"><surname>Gomersall</surname><given-names>C</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>C</given-names></name><name name-style="western"><surname>Hylander</surname><given-names>M&#248;ller M</given-names></name><name name-style="western"><surname>Iwashyna</surname><given-names>T</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>S</given-names></name><name name-style="western"><surname>Kleinpell</surname><given-names>R</given-names></name><name name-style="western"><surname>Klompas</surname><given-names>M</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwizera</surname><given-names>A</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>S</given-names></name><name name-style="western"><surname>Masur</surname><given-names>H</given-names></name><name name-style="western"><surname>McGloughlin</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mer</surname><given-names>M</given-names></name><name name-style="western"><surname>Nunnally</surname><given-names>M</given-names></name><name name-style="western"><surname>Oczkowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>T</given-names></name><name name-style="western"><surname>Papathanassoglou</surname><given-names>E</given-names></name><name name-style="western"><surname>Perner</surname><given-names>A</given-names></name><name name-style="western"><surname>Puskarich</surname><given-names>M</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J</given-names></name><name name-style="western"><surname>Schweickert</surname><given-names>W</given-names></name><name name-style="western"><surname>Seckel</surname><given-names>M</given-names></name><name name-style="western"><surname>Sevransky</surname><given-names>J</given-names></name><name name-style="western"><surname>Sprung</surname><given-names>CL</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>J</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M</given-names></name></person-group><article-title>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021</article-title><source>Crit Care Med</source><year>2021</year><volume>49</volume><fpage>e1063</fpage><lpage>e1143</lpage><pub-id pub-id-type="pmid">34605781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000005337</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>MD</given-names></name><name name-style="western"><surname>Braun</surname><given-names>LA</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>LM</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>RV</given-names></name><name name-style="western"><surname>Qualy</surname><given-names>RL</given-names></name><name name-style="western"><surname>Linde-Zwirble</surname><given-names>W</given-names></name></person-group><article-title>Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care</article-title><source>Crit Care</source><year>2004</year><volume>8</volume><fpage>R291</fpage><lpage>R298</lpage><pub-id pub-id-type="pmid">15469571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc2893</pub-id><pub-id pub-id-type="pmcid">PMC1065011</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P</given-names></name><name name-style="western"><surname>Taha</surname><given-names>M</given-names></name><name name-style="western"><surname>Soubani</surname><given-names>AO</given-names></name></person-group><article-title>Sepsis Hospitalizations With Versus Without Cancer: Epidemiology, Outcomes, and Trends in Nationwide Analysis From 2008 to 2017</article-title><source>Am J Clin Oncol</source><year>2021</year><volume>44</volume><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">34342290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/COC.0000000000000859</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudiol</surname><given-names>C</given-names></name><name name-style="western"><surname>Albasanz-Puig</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuervo</surname><given-names>G</given-names></name><name name-style="western"><surname>Carratal&#224;</surname><given-names>J</given-names></name></person-group><article-title>Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>636547</fpage><pub-id pub-id-type="pmid">33869250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.636547</pub-id><pub-id pub-id-type="pmcid">PMC8044357</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YG</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KS</given-names></name></person-group><article-title>High 28-day mortality in critically ill patients with sepsis and concomitant active cancer</article-title><source>J Int Med Res</source><year>2018</year><volume>46</volume><fpage>5030</fpage><lpage>5039</lpage><pub-id pub-id-type="pmid">30088429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060518789040</pub-id><pub-id pub-id-type="pmcid">PMC6300972</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hensley</surname><given-names>MK</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>JP</given-names></name><name name-style="western"><surname>Carlton</surname><given-names>EF</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name></person-group><article-title>Epidemiology and Outcomes of Cancer-Related Versus Non-Cancer-Related Sepsis Hospitalizations</article-title><source>Crit Care Med</source><year>2019</year><volume>47</volume><fpage>1310</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">31356477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000003896</pub-id><pub-id pub-id-type="pmcid">PMC6815199</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>SM</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chao</surname><given-names>PW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CM</given-names></name><name name-style="western"><surname>Shih</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YT</given-names></name></person-group><article-title>Long-Term Mortality and Major Adverse Cardiovascular Events in Sepsis Survivors. A Nationwide Population-based Study</article-title><source>Am J Respir Crit Care Med</source><year>2016</year><volume>194</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">26808711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201510-2023OC</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Keller</surname><given-names>SP</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C</given-names></name><name name-style="western"><surname>Glotzbecker</surname><given-names>BE</given-names></name><name name-style="western"><surname>Klompas</surname><given-names>M</given-names></name><name name-style="western"><surname>Baron</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>C</given-names></name></person-group><article-title>Improvements in Sepsis-associated Mortality in Hospitalized Patients with Cancer versus Those without Cancer. A 12-Year Analysis Using Clinical Data</article-title><source>Ann Am Thorac Soc</source><year>2020</year><volume>17</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">31800299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.201909-655OC</pub-id><pub-id pub-id-type="pmcid">PMC7175974</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Healthcare</surname><given-names>Cost and Utilization Project</given-names></name></person-group><comment>NIS Overview. [cited 28 August 2024]. Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hcup-us.ahrq.gov/nisoverview.jsp">https://www.hcup-us.ahrq.gov/nisoverview.jsp</uri></comment></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>United</surname><given-names>States Centers For Disease Control And Prevention</given-names></name></person-group><comment>ICD-10-CM. Jun 7, 2024. [cited 28 August 2024]. Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/icd/icd-10-cm.htm">https://www.cdc.gov/nchs/icd/icd-10-cm.htm</uri></comment></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Healthcare</surname><given-names>Cost and Utilization Project</given-names></name></person-group><comment>Clinical Classifications Software Refined (CCSR)For ICD-10-CM Diagnoses. [cited 28 August 2024]. Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https:www.hcup-us.ahrq.gov/toolssoftware/ccsr/dxccsr.jsp">https:www.hcup-us.ahrq.gov/toolssoftware/ccsr/dxccsr.jsp</uri></comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>E</given-names></name><name name-style="western"><surname>Oshri</surname><given-names>A</given-names></name><name name-style="western"><surname>Zapolski</surname><given-names>TCB</given-names></name><name name-style="western"><surname>Zuercher</surname><given-names>H</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>SM</given-names></name></person-group><article-title>Substance use trajectories among emerging adult Black men: Risk factors and consequences</article-title><source>Drug Alcohol Rev</source><year>2023</year><volume>42</volume><fpage>1816</fpage><lpage>1824</lpage><pub-id pub-id-type="pmid">37486247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13728</pub-id><pub-id pub-id-type="pmcid">PMC10805973</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahuja</surname><given-names>M</given-names></name><name name-style="western"><surname>Haeny</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bucholz</surname><given-names>KK</given-names></name></person-group><article-title>Perceived racial and social class discrimination and cannabis involvement among Black youth and young adults</article-title><source>Drug Alcohol Depend</source><year>2022</year><volume>232</volume><fpage>109304</fpage><pub-id pub-id-type="pmid">35124388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2022.109304</pub-id><pub-id pub-id-type="pmcid">PMC10228548</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azizoddin</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ulahannan</surname><given-names>SV</given-names></name><name name-style="western"><surname>Henson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>AC</given-names></name><name name-style="western"><surname>Moore</surname><given-names>KN</given-names></name><name name-style="western"><surname>Holman</surname><given-names>LL</given-names></name><name name-style="western"><surname>Boozary</surname><given-names>LK</given-names></name><name name-style="western"><surname>Sifat</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kendzor</surname><given-names>DE</given-names></name></person-group><article-title>Cannabis use among adults undergoing cancer treatment</article-title><source>Cancer</source><year>2023</year><volume>129</volume><fpage>3498</fpage><lpage>3508</lpage><pub-id pub-id-type="pmid">37354093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.34922</pub-id><pub-id pub-id-type="pmcid">PMC11070130</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="webpage"><comment>Interactive NSDUH State Estimates. [cited 28 August 2024]. Database: Substance Abuse and Mental Health Services Administration. [Internet]. Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://datatools.samhsa.gov/saes/state">https://datatools.samhsa.gov/saes/state</uri></comment></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacek</surname><given-names>LR</given-names></name><name name-style="western"><surname>Martins</surname><given-names>SS</given-names></name><name name-style="western"><surname>Crum</surname><given-names>RM</given-names></name></person-group><article-title>The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample</article-title><source>J Affect Disord</source><year>2013</year><volume>148</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">23260381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2012.11.059</pub-id><pub-id pub-id-type="pmcid">PMC3608823</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padwa</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>L</given-names></name><name name-style="western"><surname>Grella</surname><given-names>CE</given-names></name><name name-style="western"><surname>Urada</surname><given-names>D</given-names></name><name name-style="western"><surname>Bell</surname><given-names>DS</given-names></name><name name-style="western"><surname>Bass</surname><given-names>B</given-names></name><name name-style="western"><surname>Boustead</surname><given-names>AE</given-names></name></person-group><article-title>Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state</article-title><source>Subst Abuse Treat Prev Policy</source><year>2022</year><volume>17</volume><fpage>36</fpage><pub-id pub-id-type="pmid">35527269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13011-022-00467-1</pub-id><pub-id pub-id-type="pmcid">PMC9080201</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Ledent</surname><given-names>C</given-names></name><name name-style="western"><surname>Parmentier</surname><given-names>M</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>R</given-names></name><name name-style="western"><surname>Valverde</surname><given-names>O</given-names></name></person-group><article-title>Involvement of CB1 cannabinoid receptors in emotional behaviour</article-title><source>Psychopharmacology (Berl)</source><year>2002</year><volume>159</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">11823890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-001-0946-5</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>Giacomo V</given-names></name><name name-style="western"><surname>Ruehle</surname><given-names>S</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>B</given-names></name><name name-style="western"><surname>H&#228;ring</surname><given-names>M</given-names></name><name name-style="western"><surname>Remmers</surname><given-names>F</given-names></name></person-group><article-title>Differential glutamatergic and GABAergic contributions to the tetrad effects of &#916;(9)-tetrahydrocannabinol revealed by cell-type-specific reconstitution of the CB1 receptor</article-title><source>Neuropharmacology</source><year>2020</year><volume>179</volume><fpage>108287</fpage><pub-id pub-id-type="pmid">32860777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2020.108287</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>IM</given-names></name><name name-style="western"><surname>Wright</surname><given-names>A</given-names></name><name name-style="western"><surname>Peteet</surname><given-names>J</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>FL</given-names></name><name name-style="western"><surname>Yuppa</surname><given-names>DP</given-names></name><name name-style="western"><surname>Bolcic-Jankovic</surname><given-names>D</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>MM</given-names></name><name name-style="western"><surname>Tulsky</surname><given-names>JA</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>J</given-names></name><name name-style="western"><surname>Nabati</surname><given-names>L</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>EG</given-names></name></person-group><article-title>Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>1957</fpage><lpage>1962</lpage><pub-id pub-id-type="pmid">29746226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.76.1221</pub-id><pub-id pub-id-type="pmcid">PMC6553839</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pergam</surname><given-names>SA</given-names></name><name name-style="western"><surname>Woodfield</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>GS</given-names></name><name name-style="western"><surname>Baker</surname><given-names>KK</given-names></name><name name-style="western"><surname>Marquis</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fann</surname><given-names>JR</given-names></name></person-group><article-title>Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>4488</fpage><lpage>4497</lpage><pub-id pub-id-type="pmid">28944449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.30879</pub-id><pub-id pub-id-type="pmcid">PMC5698756</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salz</surname><given-names>T</given-names></name><name name-style="western"><surname>Meza</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chino</surname><given-names>F</given-names></name><name name-style="western"><surname>Mao</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Raghunathan</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Jinna</surname><given-names>S</given-names></name><name name-style="western"><surname>Brens</surname><given-names>J</given-names></name><name name-style="western"><surname>Furberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Korenstein</surname><given-names>D</given-names></name></person-group><article-title>Cannabis use among recently treated cancer patients: perceptions and experiences</article-title><source>Support Care Cancer</source><year>2023</year><volume>31</volume><fpage>545</fpage><pub-id pub-id-type="pmid">37650961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-023-07994-y</pub-id><pub-id pub-id-type="pmcid">PMC10585595</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawley</surname><given-names>P</given-names></name><name name-style="western"><surname>Gobbo</surname><given-names>M</given-names></name></person-group><article-title>Cannabis use in cancer: a survey of the current state at BC Cancer before recreational legalization in Canada</article-title><source>Curr Oncol</source><year>2019</year><volume>26</volume><fpage>e425</fpage><lpage>e432</lpage><pub-id pub-id-type="pmid">31548810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/co.26.4743</pub-id><pub-id pub-id-type="pmcid">PMC6726263</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>L</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></name><name name-style="western"><surname>O'Malley</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>JC</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>IS</given-names></name></person-group><article-title>Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition</article-title><source>Drug Alcohol Rev</source><year>2022</year><volume>41</volume><fpage>1095</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">35172040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13444</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turna</surname><given-names>J</given-names></name><name name-style="western"><surname>Balodis</surname><given-names>I</given-names></name><name name-style="western"><surname>Munn</surname><given-names>C</given-names></name><name name-style="western"><surname>Van</surname><given-names>Ameringen M</given-names></name><name name-style="western"><surname>Busse</surname><given-names>J</given-names></name><name name-style="western"><surname>MacKillop</surname><given-names>J</given-names></name></person-group><article-title>Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users</article-title><source>Compr Psychiatry</source><year>2020</year><volume>102</volume><fpage>152188</fpage><pub-id pub-id-type="pmid">32653594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.comppsych.2020.152188</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruger</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>JS</given-names></name><name name-style="western"><surname>Collins</surname><given-names>RL</given-names></name></person-group><article-title>Cannabis Enthusiasts' Knowledge of Medical Treatment Effectiveness and Increased Risks From Cannabis Use</article-title><source>Am J Health Promot</source><year>2020</year><volume>34</volume><fpage>436</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">31916839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0890117119899218</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkie</surname><given-names>G</given-names></name><name name-style="western"><surname>Sakr</surname><given-names>B</given-names></name><name name-style="western"><surname>Rizack</surname><given-names>T</given-names></name></person-group><article-title>Medical Marijuana Use in Oncology: A Review</article-title><source>JAMA Oncol</source><year>2016</year><volume>2</volume><fpage>670</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">26986677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.0155</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machado</surname><given-names>Rocha FC</given-names></name><name name-style="western"><surname>St&#233;fano</surname><given-names>SC</given-names></name><name name-style="western"><surname>De</surname><given-names>C&#225;ssia Haiek R</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>Oliveira LM</given-names></name><name name-style="western"><surname>Da</surname><given-names>Silveira DX</given-names></name></person-group><article-title>Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis</article-title><source>Eur J Cancer Care (Engl)</source><year>2008</year><volume>17</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">18625004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2354.2008.00917.x</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><collab>Cannabis-In-Cachexia-Study-Group</collab><person-group person-group-type="author"><name name-style="western"><surname>Strasser</surname><given-names>F</given-names></name><name name-style="western"><surname>Luftner</surname><given-names>D</given-names></name><name name-style="western"><surname>Possinger</surname><given-names>K</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>G</given-names></name><name name-style="western"><surname>Ruhstaller</surname><given-names>T</given-names></name><name name-style="western"><surname>Meissner</surname><given-names>W</given-names></name><name name-style="western"><surname>Ko</surname><given-names>YD</given-names></name><name name-style="western"><surname>Schnelle</surname><given-names>M</given-names></name><name name-style="western"><surname>Reif</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>T</given-names></name></person-group><article-title>Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3394</fpage><lpage>3400</lpage><pub-id pub-id-type="pmid">16849753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.05.1847</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>IM</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>DI</given-names></name><name name-style="western"><surname>Blansky</surname><given-names>SE</given-names></name><name name-style="western"><surname>Pergam</surname><given-names>SA</given-names></name></person-group><article-title>Cannabis and the Cancer Patient</article-title><source>J Natl Cancer Inst Monogr</source><year>2021</year><volume>2021</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">34850899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncimonographs/lgab012</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>S</given-names></name><name name-style="western"><surname>Shekher</surname><given-names>A</given-names></name><name name-style="western"><surname>Puneet</surname></name><name name-style="western"><surname>Narula</surname><given-names>AS</given-names></name><name name-style="western"><surname>Abrahamse</surname><given-names>H</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>SC</given-names></name></person-group><article-title>Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities</article-title><source>Pharmacol Res</source><year>2021</year><volume>163</volume><fpage>105302</fpage><pub-id pub-id-type="pmid">33246167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2020.105302</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kicman</surname><given-names>A</given-names></name><name name-style="western"><surname>Toczek</surname><given-names>M</given-names></name></person-group><article-title>The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>6740</fpage><pub-id pub-id-type="pmid">32937917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21186740</pub-id><pub-id pub-id-type="pmcid">PMC7554803</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jean-Gilles</surname><given-names>L</given-names></name><name name-style="western"><surname>Gran</surname><given-names>B</given-names></name><name name-style="western"><surname>Constantinescu</surname><given-names>CS</given-names></name></person-group><article-title>Interaction between cytokines, cannabinoids and the nervous system</article-title><source>Immunobiology</source><year>2010</year><volume>215</volume><fpage>606</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">20153076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2009.12.006</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pellati</surname><given-names>F</given-names></name><name name-style="western"><surname>Borgonetti</surname><given-names>V</given-names></name><name name-style="western"><surname>Brighenti</surname><given-names>V</given-names></name><name name-style="western"><surname>Biagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Benvenuti</surname><given-names>S</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>L</given-names></name></person-group><article-title>Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer</article-title><source>Biomed Res Int</source><year>2018</year><volume>2018</volume><fpage>1691428</fpage><pub-id pub-id-type="pmid">30627539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/1691428</pub-id><pub-id pub-id-type="pmcid">PMC6304621</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martini</surname><given-names>S</given-names></name><name name-style="western"><surname>Gemma</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>M</given-names></name><name name-style="western"><surname>Marino</surname><given-names>F</given-names></name></person-group><article-title>Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>3125</fpage><pub-id pub-id-type="pmid">36834537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24043125</pub-id><pub-id pub-id-type="pmcid">PMC9964491</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinu</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rogobete</surname><given-names>AF</given-names></name><name name-style="western"><surname>Bratu</surname><given-names>T</given-names></name><name name-style="western"><surname>Popovici</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bedreag</surname><given-names>OH</given-names></name><name name-style="western"><surname>Papurica</surname><given-names>M</given-names></name><name name-style="western"><surname>Bratu</surname><given-names>LM</given-names></name><name name-style="western"><surname>Sandesc</surname><given-names>D</given-names></name></person-group><article-title>Cannabis Sativa Revisited-Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>307</fpage><pub-id pub-id-type="pmid">32012914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9020307</pub-id><pub-id pub-id-type="pmcid">PMC7072707</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gojani</surname><given-names>EG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>DP</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>O</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>I</given-names></name></person-group><article-title>Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages</article-title><source>Molecules</source><year>2023</year><volume>28</volume><fpage>6487</fpage><pub-id pub-id-type="pmid">37764262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28186487</pub-id><pub-id pub-id-type="pmcid">PMC10534668</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>MP</given-names></name></person-group><article-title>Cannabinoids for Symptom Management and Cancer Therapy: The Evidence</article-title><source>J Natl Compr Canc Netw</source><year>2016</year><volume>14</volume><fpage>915</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">27407130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2016.0094</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>PY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XP</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>SD</given-names></name><name name-style="western"><surname>Xu</surname><given-names>YX</given-names></name><name name-style="western"><surname>Du</surname><given-names>XH</given-names></name></person-group><article-title>Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1094020</fpage><pub-id pub-id-type="pmid">36755953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1094020</pub-id><pub-id pub-id-type="pmcid">PMC9899821</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumeister</surname><given-names>SE</given-names></name><name name-style="western"><surname>Baurecht</surname><given-names>H</given-names></name><name name-style="western"><surname>Nolde</surname><given-names>M</given-names></name><name name-style="western"><surname>Alayash</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gl&#228;ser</surname><given-names>S</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>M</given-names></name><name name-style="western"><surname>Amos</surname><given-names>CI</given-names></name></person-group><collab>International Lung Cancer Consortium, Johnson EC, Hung RJ</collab><article-title>Cannabis Use, Pulmonary Function, and Lung Cancer Susceptibility: A Mendelian Randomization Study</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">33852959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2021.03.025</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomko</surname><given-names>AM</given-names></name><name name-style="western"><surname>Whynot</surname><given-names>EG</given-names></name><name name-style="western"><surname>O'Leary</surname><given-names>LF</given-names></name><name name-style="western"><surname>Dupr&#233;</surname><given-names>DJ</given-names></name></person-group><article-title>Anti-cancer potential of cannabis terpenes in a Taxol-resistant model of breast cancer</article-title><source>Can J Physiol Pharmacol</source><year>2022</year><volume>100</volume><fpage>806</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">35704944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1139/cjpp-2021-0792</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchtova</surname><given-names>T</given-names></name><name name-style="western"><surname>Lukac</surname><given-names>D</given-names></name><name name-style="western"><surname>Skrott</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chroma</surname><given-names>K</given-names></name><name name-style="western"><surname>Bartek</surname><given-names>J</given-names></name><name name-style="western"><surname>Mistrik</surname><given-names>M</given-names></name></person-group><article-title>Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>2885</fpage><pub-id pub-id-type="pmid">36769206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032885</pub-id><pub-id pub-id-type="pmcid">PMC9917508</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twelves</surname><given-names>C</given-names></name><name name-style="western"><surname>Sabel</surname><given-names>M</given-names></name><name name-style="western"><surname>Checketts</surname><given-names>D</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S</given-names></name><name name-style="western"><surname>Tayo</surname><given-names>B</given-names></name><name name-style="western"><surname>Jove</surname><given-names>M</given-names></name><name name-style="western"><surname>Brazil</surname><given-names>L</given-names></name><name name-style="western"><surname>Short</surname><given-names>SC</given-names></name></person-group><collab>GWCA1208 study group</collab><article-title>A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma</article-title><source>Br J Cancer</source><year>2021</year><volume>124</volume><fpage>1379</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">33623076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-021-01259-3</pub-id><pub-id pub-id-type="pmcid">PMC8039032</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>IM</given-names></name><name name-style="western"><surname>Bohlke</surname><given-names>K</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>DI</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>H</given-names></name><name name-style="western"><surname>Balneaves</surname><given-names>LG</given-names></name><name name-style="western"><surname>Bar-Sela</surname><given-names>G</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>DW</given-names></name><name name-style="western"><surname>Chai</surname><given-names>PR</given-names></name><name name-style="western"><surname>Damani</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Hallmeyer</surname><given-names>S</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>IM</given-names></name><name name-style="western"><surname>Twelves</surname><given-names>C</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>MS</given-names></name><name name-style="western"><surname>Roeland</surname><given-names>EJ</given-names></name></person-group><article-title>Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline</article-title><source>J Clin Oncol</source><year>2024</year><volume>42</volume><fpage>1575</fpage><lpage>1593</lpage><pub-id pub-id-type="pmid">38478773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02596</pub-id><pub-id pub-id-type="pmcid">PMC11730458</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Amna</surname><given-names>M</given-names></name><name name-style="western"><surname>Salti</surname><given-names>T</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>I</given-names></name><name name-style="western"><surname>Bar-Sela</surname><given-names>G</given-names></name></person-group><article-title>Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?</article-title><source>Curr Treat Options Oncol</source><year>2021</year><volume>22</volume><fpage>16</fpage><pub-id pub-id-type="pmid">33439370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11864-020-00811-2</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravda</surname><given-names>J</given-names></name></person-group><article-title>Metabolic theory of septic shock</article-title><source>World J Crit Care Med</source><year>2014</year><volume>3</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">24892019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5492/wjccm.v3.i2.45</pub-id><pub-id pub-id-type="pmcid">PMC4038812</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>A</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>C</given-names></name></person-group><article-title>Betacaryophyllene - A phytocannabinoid as potential therapeutic modality for human sepsis?</article-title><source>Med Hypotheses</source><year>2018</year><volume>110</volume><fpage>68</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">29317072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2017.10.025</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffre</surname><given-names>J</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E</given-names></name><name name-style="western"><surname>Thete</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zlatanova</surname><given-names>I</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>E</given-names></name><name name-style="western"><surname>Kobzik</surname><given-names>L</given-names></name><name name-style="western"><surname>Legrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Hellman</surname><given-names>J</given-names></name></person-group><article-title>Activation of CB(1)R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells&#160;and Reduces Acute Inflammation and Organ Injury</article-title><source>J Immunol</source><year>2020</year><volume>204</volume><fpage>3339</fpage><lpage>3350</lpage><pub-id pub-id-type="pmid">32385136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000213</pub-id><pub-id pub-id-type="pmcid">PMC7276941</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maayah</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Ferdaoussi</surname><given-names>M</given-names></name><name name-style="western"><surname>Alam</surname><given-names>A</given-names></name><name name-style="western"><surname>Takahara</surname><given-names>S</given-names></name><name name-style="western"><surname>Silver</surname><given-names>H</given-names></name><name name-style="western"><surname>Soni</surname><given-names>S</given-names></name><name name-style="western"><surname>Martens</surname><given-names>MD</given-names></name><name name-style="western"><surname>Eurich</surname><given-names>DT</given-names></name><name name-style="western"><surname>Dyck</surname><given-names>JRB</given-names></name></person-group><article-title>Cannabidiol Suppresses Cytokine Storm and Protects Against Cardiac and Renal Injury Associated with Sepsis</article-title><source>Cannabis Cannabinoid Res</source><year>2024</year><volume>9</volume><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">36594988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/can.2022.0170</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunasekaran</surname><given-names>K</given-names></name><name name-style="western"><surname>Voruganti</surname><given-names>DC</given-names></name><name name-style="western"><surname>Singh</surname><given-names>Rahi M</given-names></name><name name-style="western"><surname>Elango</surname><given-names>K</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>S</given-names></name><name name-style="western"><surname>Geeti</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J</given-names></name></person-group><article-title>Trends in Prevalence and Outcomes of Cannabis Use Among Chronic Obstructive Pulmonary Disease Hospitalizations: A Nationwide Population-Based Study 2005-2014</article-title><source>Cannabis Cannabinoid Res</source><year>2021</year><volume>6</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">33998884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/can.2020.0133</pub-id><pub-id pub-id-type="pmcid">PMC8380787</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vin-Raviv</surname><given-names>N</given-names></name><name name-style="western"><surname>Akinyemiju</surname><given-names>T</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sakhuja</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayward</surname><given-names>R</given-names></name></person-group><article-title>Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database</article-title><source>Cancer Med</source><year>2017</year><volume>6</volume><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">27891823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.968</pub-id><pub-id pub-id-type="pmcid">PMC5269570</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuinness</surname><given-names>B</given-names></name><name name-style="western"><surname>Goel</surname><given-names>A</given-names></name><name name-style="western"><surname>Elias</surname><given-names>F</given-names></name><name name-style="western"><surname>Rapanos</surname><given-names>T</given-names></name><name name-style="western"><surname>Mittleman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ladha</surname><given-names>KS</given-names></name></person-group><article-title>Cannabis use disorder and perioperative outcomes in vascular surgery</article-title><source>J Vasc Surg</source><year>2021</year><volume>73</volume><fpage>1376</fpage><lpage>1387.e3</lpage><pub-id pub-id-type="pmid">32861869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2020.07.094</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>C</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name></person-group><article-title>Cannabis Use and the Risk of Cardiovascular Diseases: A Mendelian Randomization Study</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>676850</fpage><pub-id pub-id-type="pmid">34409073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2021.676850</pub-id><pub-id pub-id-type="pmcid">PMC8366226</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vozoris</surname><given-names>NT</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chow</surname><given-names>CW</given-names></name><name name-style="western"><surname>To</surname><given-names>T</given-names></name></person-group><article-title>Cannabis use and risks of respiratory and all-cause morbidity and mortality: a population-based, data-linkage, cohort study</article-title><source>BMJ Open Respir Res</source><year>2022</year><volume>9</volume><fpage>e001216</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjresp-2022-001216</pub-id><pub-id pub-id-type="pmcid">PMC9240874</pub-id><pub-id pub-id-type="pmid">35760496</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data sharing statement</title><p>We used a publicly available anonymous national database, <italic toggle="yes">i.e.</italic>, the National Inpatient Sample (datasets from 2016 to 2020).</p></sec></back></article></pmc-articleset>